Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
45.04
-1.48 (-3.18%)
Nov 20, 2024, 4:00 PM EST - Market closed
Apogee Therapeutics Employees
Apogee Therapeutics had 91 employees as of December 31, 2023.
Employees
91
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,611,681
Market Cap
2.56B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 91 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PACS Group | 32,433 |
| LifeStance Health Group | 9,325 |
| Concentra Group Holdings Parent | 9,020 |
| Amneal Pharmaceuticals | 7,850 |
| QuidelOrtho | 7,100 |
| Iovance Biotherapeutics | 557 |
| Vericel | 314 |
| SpringWorks Therapeutics | 305 |
APGE News
- 2 days ago - Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - GlobeNewsWire
- 10 days ago - Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis - Seeking Alpha
- 16 days ago - Apogee Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 5 weeks ago - Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting - GlobeNewsWire
- 2 months ago - Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - GlobeNewsWire
- 2 months ago - Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer - GlobeNewsWire
- 3 months ago - Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases - GlobeNewsWire
- 3 months ago - Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results - GlobeNewsWire